Regeneron Pharmaceuticals (REGN) Net Equity Issued and Repurchased (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Net Equity Issued and Repurchased of $49.2 million for Q2 2026, up 56.19% year-over-year from $31.5 million in Q2 2025, and down 69.83% quarter-over-quarter from $163.1 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Net Equity Issued and Repurchased (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Net Equity Issued and Repurchased history runs 18 years deep, the most recent figure standing at $49.2 million for Q2 2026.
- In Q2 2026, Net Equity Issued and Repurchased rose 56.19% year-over-year to $49.2 million; the TTM figure through Jun 2026 stood at $756.1 million (up 72.74% YoY), while the FY2025 annual figure was $635.9 million, down 56.6% from the prior year.
- Net Equity Issued and Repurchased for Q2 2026 stood at $49.2 million, down from $163.1 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $682.1 million in Q1 2024, with the low at $31.5 million in Q2 2025.
- The 5-year median for Net Equity Issued and Repurchased is $284.8 million (2023), against an average of $276.6 million.
- Peak annual rise in Net Equity Issued and Repurchased reached 453.91% in 2025, while the deepest fall reached 92.8% in 2025.
- Regeneron Pharmaceuticals' Net Equity Issued and Repurchased stood at $372.6 million in 2022, then declined by 19.22% to $301.0 million in 2023, then sank by 69.8% to $90.9 million in 2024, then jumped by 453.91% to $503.5 million in 2025, then sank by 90.23% to $49.2 million in 2026.
- Business Quant data shows REGN's Net Equity Issued and Repurchased at $49.2 million in Q2 2026, $163.1 million in Q1 2026, and $503.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.20 Mn |
| Jun 30, 2026 | 49.20 Mn |
| Mar 31, 2026 | 163.10 Mn |
| Mar 31, 2026 | 163.10 Mn |
| Dec 31, 2025 | 503.50 Mn |
| Dec 31, 2025 | 503.50 Mn |
| Sep 30, 2025 | 40.30 Mn |
| Sep 30, 2025 | 40.30 Mn |
| Jun 30, 2025 | 31.50 Mn |
| Jun 30, 2025 | 31.50 Mn |
| Mar 31, 2025 | 60.60 Mn |
| Mar 31, 2025 | 60.60 Mn |
| Dec 31, 2024 | 90.90 Mn |
| Dec 31, 2024 | 90.90 Mn |
| Sep 30, 2024 | 254.70 Mn |
| Sep 30, 2024 | 254.70 Mn |
| Jun 30, 2024 | 437.60 Mn |
| Jun 30, 2024 | 437.60 Mn |
| Mar 31, 2024 | 682.10 Mn |
| Mar 31, 2024 | 682.10 Mn |